(1R,3S,4S)-2-methyl-2-azabicyclo[2.2.1]heptane-3-carboxylic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1R,3S,4S)-2-methyl-2-azabicyclo[2.2.1]heptane-3-carboxylic acid
• 化学式: C₈H₁₃NO₂
• 分子量: 155.19
• InChiKey: OKAZYRYKXFWBBU-XVMARJQXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• NOVEL SUBSTITUTED SPIROCYCLES
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20160075704A1

  公开（公告）日：2016-03-17

  This invention relates to a compound of formula I wherein A and Cy have one of the meanings as indicated in the specification and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.

  这项发明涉及一种具有式I的化合物 其中A和Cy具有规范中指示的含义之一，以及它们作为Cathepsin C的抑制剂的用途，含有这些化合物的药物组合物，以及将它们用作治疗和/或预防与二肽基肽酶I活性相关的疾病的药剂的方法，例如呼吸道疾病。
• ANTIVIRAL COMPOUNDS
  申请人：GILEAD PHARMASSET LLC

  公开号：US20150353529A1

  公开（公告）日：2015-12-10

  The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  本发明涉及抗病毒化合物、含有这种化合物的组合物、包括给予这种化合物的治疗方法，以及用于制备这种化合物的过程和中间体。
• US20140275114A1
  申请人：——

  公开号：US20140275114A1

  公开（公告）日：2014-09-18
• SUBSTITUTED OXETANES AND THEIR USE AS INHIBITORS OF CATHEPSIN C
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20160031861A1

  公开（公告）日：2016-02-04

  This invention relates to a compound of formula I and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.
• ANTIBODY DRUG CONJUGATES
  申请人：ABRAMS Tinya

  公开号：US20190194315A1

  公开（公告）日：2019-06-27

  This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments, particularly antibody drug conjugates comprising anti-P-cadherin antibodies conjugated to auristatin analogs. The invention also relates to methods of treating cancer using the antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.